Luseogliflozin hydrate is a medication for managing type 2 diabetes mellitus (T2DM) by improving glycemic control. As a sodium-glucose cotransporter 2 (SGLT2) inhibitor, it works by helping the kidneys excrete excess glucose from the blood into the urine. It can also lead to other benefits including lowering body weight, blood pressure, and triglycerides, particularly in patients with higher BMI. It is grouped under the following drug class(es): Hypoglycemics and SGLT2 inhibitors. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Luseogliflozin hemihydrate and Tafolec. Its PubChem CID is 56928196.
Luseogliflozin hydrate
| CAS No | 1152425-66-5 |
|---|---|
| Molecular Formula | C23H32O7S |
| Molecular Weight | 452.60 g/mol |
| Synonyms | (2S,3R,4R,5S,6R)-2-[5-[(4-ethoxyphenyl)methyl]-2-methoxy-4-methylphenyl]-6-(hydroxymethyl)thiane-3,4,5-triol;hydrate |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Luseogliflozin hydrate is a medication for managing type 2 diabetes mellitus (T2DM) by improving glycemic control. As a sodium-glucose cotransporter 2 (SGLT2) inhibitor, it works by helping the kidneys excrete excess glucose from the blood into the urine.
The listed CAS number is 1152425-66-5.
The listed molecular formula is C23H32O7S.
The listed molecular weight is 452.60 g/mol.
(2S,3R,4R,5S,6R)-2-[5-[(4-ethoxyphenyl)methyl]-2-methoxy-4-methylphenyl]-6-(hydroxymethyl)thiane-3,4,5-triol;hydrate.
The source lists Luseogliflozin hemihydrate and Tafolec.